Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells

Supplementary data of the experiment: Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells.". Hepatocellular carcinoma (HCC) is a prevalent type of tumor. Given the controversy surrounding atorvastatin and HCC, we conducted this study to determine whether atorvastatin has anticancer activity against HCC.Methods: The impact of varying concentrations of atorvastatin (ATO) on the biological function of HCC cells was studied in vitro with high-throughput mRNA assays on cells.